Literature DB >> 31513703

Polymyxin Resistance in Klebsiella pneumoniae: Complexity at Every Level.

Yohei Doi1,2,3, David van Duin4.   

Abstract

Entities:  

Keywords:  zzm321990 Klebsiella pneumoniaezzm321990 ; carbapenem-resistant Enterobacteriaceae; colistin resistance

Year:  2020        PMID： 31513703      PMCID： PMC7201414          DOI： 10.1093/cid/ciz627

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  21 in total

Review 1.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

2.  Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

Authors:  James A McKinnell; Jamie P Dwyer; George H Talbot; Lynn E Connolly; Ian Friedland; Alex Smith; Adrian M Jubb; Alisa W Serio; Kevin M Krause; George L Daikos
Journal:  N Engl J Med       Date:  2019-02-21       Impact factor: 91.245

3.  Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.

Authors:  Zubair A Qureshi; Lauren E Hittle; Jessica A O'Hara; Jesabel I Rivera; Alveena Syed; Ryan K Shields; Anthony W Pasculle; Robert K Ernst; Yohei Doi
Journal:  Clin Infect Dis       Date:  2015-01-28       Impact factor: 9.079

4.  The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.

Authors:  Yael Dishon Benattar; Muna Omar; Oren Zusman; Dafna Yahav; Yael Zak-Doron; Sergey Altunin; Michal Elbaz; Vered Daitch; Michal Granot; Leonard Leibovici; Mical Paul
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

5.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Traced to Clonal Expansion of an mgrB Deletion Mutant.

Authors:  Tommaso Giani; Fabio Arena; Guendalina Vaggelli; Viola Conte; Adriana Chiarelli; Lucia Henrici De Angelis; Rossella Fornaini; Maddalena Grazzini; Fabrizio Niccolini; Patrizia Pecile; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

7.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Authors:  Mical Paul; George L Daikos; Emanuele Durante-Mangoni; Dafna Yahav; Yehuda Carmeli; Yael Dishon Benattar; Anna Skiada; Roberto Andini; Noa Eliakim-Raz; Amir Nutman; Oren Zusman; Anastasia Antoniadou; Pia Clara Pafundi; Amos Adler; Yaakov Dickstein; Ioannis Pavleas; Rosa Zampino; Vered Daitch; Roni Bitterman; Hiba Zayyad; Fidi Koppel; Inbar Levi; Tanya Babich; Lena E Friberg; Johan W Mouton; Ursula Theuretzbacher; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2018-02-16       Impact factor: 25.071

8.  Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Alberto Corona; Francesco Giuseppe De Rosa; Matteo Bassetti; Cristina Mussini; Francesco Menichetti; Claudio Viscoli; Caterina Campoli; Mario Venditti; Andrea De Gasperi; Alessandra Mularoni; Carlo Tascini; Giustino Parruti; Carlo Pallotto; Simona Sica; Ercole Concia; Rosario Cultrera; Gennaro De Pascale; Alessandro Capone; Spinello Antinori; Silvia Corcione; Elda Righi; Angela Raffaella Losito; Margherita Digaetano; Francesco Amadori; Daniele Roberto Giacobbe; Giancarlo Ceccarelli; Ernestina Mazza; Francesca Raffaelli; Teresa Spanu; Roberto Cauda; Pierluigi Viale
Journal:  Clin Infect Dis       Date:  2019-01-18       Impact factor: 9.079

9.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

10.  Structural modification of LPS in colistin-resistant, KPC-producing Klebsiella pneumoniae.

Authors:  Lisa M Leung; Vaughn S Cooper; David A Rasko; Qinglan Guo; Marissa P Pacey; Christi L McElheny; Roberta T Mettus; Sung Hwan Yoon; David R Goodlett; Robert K Ernst; Yohei Doi
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790
View more
  2 in total

1.  Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.

Authors:  Lin Qi; Rongxin Liang; Jingjing Duan; Songze Song; Yunjun Pan; Hui Liu; Mingan Zhu; Lian Li
Journal:  J Antibiot (Tokyo)       Date:  2022-08-23       Impact factor: 3.424

2.  A Potent Antibiotic Combination of Linezolid and Polymycin B Nonapeptide Against Klebsiella pneumoniae Infection In Vitro and In Vivo.

Authors:  Ting Huang; Zheng Lv; Jiafu Lin; Kelei Zhao; Longfei Zhai; Xinrong Wang; Yiwen Chu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.